MDM2 regulates estrogen receptor α and estrogen responsiveness in breast cancer cells

Journal of Molecular Endocrinology

Volumn 46, Issue 2, 2011, Pages 67-79

  Kim, Kyounghyun ^a,b   Burghardt, Robert ^c   Barhoumi, Rola ^c   Lee, Syng ook ^b   Liu, Xinyi ^d   Safe, Stephen ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c Departments of Veterinary Integrative Biosciences   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; PROTEIN MDM2;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DELETION MUTANT; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION; HUMANS; MICE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; RNA INTERFERENCE; SEQUENCE DELETION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 79953692088     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-10-0110     Document Type: Article

References (53)

1. Akaogi K, Nakajima Y, Ito I, Kawasaki S, Oie SH, Murayama A, Kimura K & Yanagisawa J 2009 KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha. Oncogene 28 2894-2902. (doi:10.1038/onc.2009.151)
2. Ashcroft M, Kubbutat MH & Vousden KH 1999 Regulation of p53 function and stability by phosphorylation. Molecular and Cellular Biology 19 1751-1758.
3. Blanco JC, Minucci S, Lu J, Yang XJ, Walker KK, Chen H, Evans RM, Nakatani Y & Ozato K 1998 The histone acetylase PCAF is a nuclear receptor coactivator. Genes and Development 12 1638-1651. (doi:10. 1101/gad.12.11.1638)
4. Brooks CL & Gu W 2006 p53 ubiquitination: Mdm2 and beyond. Molecular Cell 21 307-315. (doi:10.1016/j.molcel.2006.01.020)
5. Bueso-Ramos CE, Manshouri T, Haidar MA, Yang Y, McCown P, Ordonez N, Glassman A, Sneige N & Albitar M 1996 Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Research and Treatment 37 179-188. (doi:10.1007/BF01806499)
6. Burakov D, Crofts LA, Chang CPB & Freedman LP 2002 Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor. Journal of Biological Chemistry 277 14359-14362. (doi:10.1074/jbc.C200099200)
7. Cahilly-Snyder L, Yang-Feng T, Francke U & George DL 1987 Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell and Molecular Genetics 13 235-244. (doi:10.1007/BF01535205)
8. Chen DG, Huang SM & Stallcup MR 2000 Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. Journal of Biological Chemistry 275 40810-40816. (doi:10.1074/jbc.M005459200)
9. Fakharzadeh SS, Trusko SP & George DL 1991 Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO Journal 10 1565-1569.
10. Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX, Kumar S, Howley PM & Livingston DM 1998 p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Molecular Cell 2 405-415. (doi:10.1016/S1097-2765(00)80140-9)
11. Hall JM, Couse JF & Korach KS 2001 The multifaceted mechanisms of estradiol and estrogen receptor signaling. Journal of Biological Chemistry 276 36869-36872. (doi:10.1074/jbc.R100029200)
12. Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R & Brown M 1996 p300 is a component of an estrogen receptor coactivator complex. PNAS 93 11540-11545. (doi:10.1073/ pnas.93.21.11540)
13. Hori M, Shimazaki J, Inagawa S, Itabashi M & Hori M 2002 Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor α and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Research and Treatment 71 77-83. (doi:10.1023/A:1013350419426)
14. Hsieh JK, Chan FS, O'Connor DJ, Mittnacht S, Zhong S & Lu X 1999 RB regulates the stability and the apoptotic function of p53 via MDM2. Molecular Cell 3 181-193. (doi:10.1016/S1097-2765(00)80309-3)
15. Jones SN, Roe AE, Donehower LA & Bradley A 1995 Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378 206-208. (doi:10.1038/378206a0)
16. Khan S, Abdelrahim M, Samudio I & Safe S 2003 Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17β-estradiol in breast cancer cells. Endocrinology 144 2325-2335. (doi:10.1210/en.2002-0149)
17. Kim K, Nguyen T, Saville B & Safe S 2003 Domains of estrogen receptor α (ERα) required for ERα/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. Molecular Endocrinology 17 804-817. (doi:10.1210/me.2002-0406)
18. Kim K, Barhoumi R, Burghardt R & Safe S 2005 Analysis of estrogen receptor α-Sp1 interactions in breast cancer cells by fluorescence resonance energy transfer. Molecular Endocrinology 19 843-854. (doi:10.1210/me.2004-0326)
19. Koh SS, Li H, Lee YH, Widelitz RB, Chuong CM & Stallcup MR 2002 Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and β-catenin with two different classes of DNA-binding transcriptional activators. Journal of Biological Chemistry 277 26031-26035. (doi:10.1074/jbc.M110865200)
20. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A & Thomas-Tsagli E 1997 MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. British Journal of Cancer 75 1269-1278.
21. Kouzmenko AP, Takeyama K, Ito S, Furutani T, Sawatsubashi S, Maki A, Suzuki E, Kawasaki Y, Akiyama T, Tabata T. et al. 2004 Wnt/β-catenin and estrogen signaling converge in vivo. Journal of Biological Chemistry 279 40255-40258. (doi:10.1074/jbc.C400331200)
22. Kubbutat MH, Ludwig RL, Levine AJ & Vousden KH 1999 Analysis of the degradation function of Mdm2. Cell Growth and Differentiation 10 87-92.
23. Lee J & Safe S 2007 Coactivation of estrogen receptor α (ER α)/Sp1 by vitamin D receptor interacting protein 150 (DRIP150). Archives of Biochemistry and Biophysics 461 200-210. (doi:10.1016/j.abb.2006. 12.030)
24. Lee JE, Kim K, Sacchettini JC, Smith CV & Safe S 2005 DRIP150 coactivation of estrogen receptor α in ZR-75 breast cancer cells is independent of LXXLL motifs. Journal of Biological Chemistry 280 8819-8830. (doi:10.1074/jbc.M413184200)
25. Levav-Cohen Y, Haupt S & Haupt Y 2005 Mdm2 in growth signaling and cancer. Growth Factors 23 183-192. (doi:10.1080/ 08977190500196218)
26. Leveillard T & Wasylyk B 1997 The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. Journal of Biological Chemistry 272 30651-30661. (doi:10. 1074/jbc.272.49.30651)
27. Li H, Kim JH, Koh SS & Stallcup MR 2004 Synergistic effects of coactivators GRIP1 and β-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways. Journal of Biological Chemistry 279 4212-4220. (doi:10.1074/jbc.M311374200)
28. Liu G, Schwartz JA & Brooks SC 1999 p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochemical and Biophysical Research Communications 264 359-364. (doi:10.1006/bbrc.1999.1525)
29. Liu G, Schwartz JA & Brooks SC 2000 Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Research 60 1810-1814.
30. Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S & Press MF 2001 Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Research 61 3212-3219.
31. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB & Kouzarides T 1995 Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375 691-694. (doi:10.1038/ 375691a0)
32. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M & Gannon F 2003 Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 751-763. (doi:10.1016/S0092-8674(03)00934-6)
33. Momand J, Zambetti GP, Olson DC, George D & Levine AJ 1992 The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 1237-1245. (doi:10.1016/0092-8674(92)90644-R)
34. Montes de Oca Luna R, Wagner DS & Lozano G 1995 Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378 203-206. (doi:10.1038/378203a0)
35. Ngwenya S & Safe S 2003 Cell context-dependent differences in the induction of E2F-1 gene expression by 17β-estradiol in MCF-7 and ZR-75 cells. Endocrinology 144 1675-1685. (doi:10.1210/en.2002-0009)
36. O'Malley BW 2007 Coregulators: from whence came these master genes. Molecular Endocrinology 21 1009-1013. (doi:10.1210/me. 2007-0012)
37. O'Malley BW & Kumar R 2009 Nuclear receptor coregulators in cancer biology. Cancer Research 69 8217-8222. (doi:10.1158/0008-5472. CAN-09-2223)
38. Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschlager C, Heidecke V & Burkert W 1997 Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. Journal of Neuro-Oncology 35 13-28. (doi:10.1023/A:1005841520514)
39. Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J & Gannon F 2003 Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Molecular Cell 11 695-707. (doi:10.1016/S1097-2765(03)00090-X)
40. de Rozieres S, Maya R, Oren M & Lozano G 2000 The loss of mdm2 induces p53-mediated apoptosis. Oncogene 19 1691-1697. (doi:10. 1038/sj.onc.1203468)
41. Safe S & Kim K 2004 Nuclear receptor-mediated transactivation through interaction with Sp proteins. Progress in Nucleic Acid Research and Molecular Biology 77 1-36. (doi:10.1016/S0079-6603 (04)77001-4)
42. Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y, Saji S & Hayashi S 2001 MDM2 enhances the function of estrogen receptor α in human breast cancer cells. Biochemical and Biophysical Research Communications 281 259-265. (doi:10.1006/bbrc.2001. 4339)
43. Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodemann HP & Bamberg M 2000 Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. Journal of Neuro-Oncology 49 197-203. (doi:10.1023/A:1006410 702284)
44. Sengupta S & Wasylyk B 2004 Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. Annals of the New York Academy of Sciences 1024 54-71. (doi:10.1196/ annals.1321.005)
45. Shang Y, Hu X, DiRenzo J, Lazar MA & Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 843-852. (doi:10.1016/S0092-8674 (00)00188-4)
46. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK & Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387 677-684. (doi:10.1038/42652)
47. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C et al. 2004 In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 844-848. (doi:10.1126/science.1092472)
48. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ et al. 2002 A geneexpression signature as a predictor of survival in breast cancer. New England Journal of Medicine 347 1999-2009. (doi:10.1056/ NEJMoa021967)
49. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P & Gronemeyer H 1998 The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and-independent pathways. EMBO Journal 17 507-519. (doi:10.1093/emboj/17.2.507)
50. Wang W, Dong L, Saville B & Safe S 1999 Transcriptional activation of E2F1 gene expression by 17β-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Molecular Endocrinology 13 1373-1387. (doi:10.1210/me.13.8.1373)
51. Wilkening S, Bermejo JL & Hemminki K 2007 MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 28 2262-2267. (doi:10.1093/carcin/bgm191)
52. Wu Q, Burghardt R & Safe S 2004 Vitamin D-interacting protein 205 (DRIP205) coactivation of estrogen receptor α (ERα) involves multiple domains of both proteins. Journal of Biological Chemistry 279 53602-53612. (doi:10.1074/jbc.M409778200)
53. Yang CK, Kim JH, Li H & Stallcup MR 2006 Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with β-catenin or GRIP1. Journal of Biological Chemistry 281 3389-3397. (doi:10.1074/jbc. M510403200)